key: cord-0864203-lljxl73n
authors: Yamaoka, Yutaro; Miyakawa, Kei; Jeremiah, Sundararaj Stanleyraj; Funabashi, Rikako; Okudela, Koji; Kikuchi, Sayaka; Katada, Junichi; Wada, Atsuhiko; Takei, Toshiki; Nishi, Mayuko; Shimizu, Kohei; Ozawa, Hiroki; Usuku, Shuzo; Kawakami, Chiharu; Tanaka, Nobuko; Morita, Takeshi; Hayashi, Hiroyuki; Mitsui, Hideaki; Suzuki, Keita; Aizawa, Daisuke; Yoshimura, Yukihiro; Miyazaki, Tomoyuki; Yamazaki, Etsuko; Suzuki, Tadaki; Kimura, Hirokazu; Shimizu, Hideaki; Okabe, Nobuhiko; Hasegawa, Hideki; Ryo, Akihide
title: Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
date: 2021-05-16
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100311
sha: 2dd587c379bd44e974aa8171d71a257d8527484f
doc_id: 864203
cord_uid: lljxl73n

The ongoing COVID-19 pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAb) that exclusively react with SARS-CoV-2 and exhibit no cross-reactivity with other human coronaviruses including SARS-CoV. Molecular modeling suggest that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 NP mAbs using ELISA, and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Due to their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.

folded and biologically active proteins identical to those expressed in mammalian cells 20 . 1

These advantages highlight the suitability of this system for the generation of practically 2 relevant antigenic proteins that can be used to immunize animals and generate mAbs. In 3 our previous study we were able to demonstrate favorable results upon producing NP of 4

Middle-East severe respiratory syndrome (MERS) coronavirus using this system 21 . 5

In the current study, we have synthesized recombinant SARS-CoV-2 NP and 6 produced mAbs that could specifically detect this protein. We also determined the 7 optimal pair of the newly produced anti-NP mAbs to develop antigen capture ELISA and 8 lateral flow immunochromatography assay (LFIA) for sensitive and definitive detection of 9 SARS-CoV-2. 10 11 Results 12

NP has conserved amino acid (aa) residues at the N-terminal domain (NTD; aa 1-120) 14 that are homologous among human coronaviruses 22 . We produced N-terminal truncated 15 nucleocapsid protein (∆N-NP; aa 121-419) devoid of the homologous residues and used 16 it as an immunogen to produce mAbs that are specific for SARS-CoV-2. His-tagged ∆N-17 NP was successfully expressed using wheat germ extracts and was purified as a soluble 18 protein for immunization to BALB/c mice (Supplementary Figure 1A) . After 4 weeks of 19 immunization, lymphocytes were harvested from the immunized mice and were fused 20 with mouse myeloma cells to establish 144 stable hybridomas designated as #1-144 21 ( Figure 1A ). The mAbs generated from these hybridomas were subjected to assess their 22 reactivity to intact NP antigen by indirect ELISA, AlphaScreen, and Bio-Layer 23 Interferometry ( Figure 1B) . Consequently, we selected 12 hybridoma clones that had 24 high reactivity and affinity to the antigen in all three methods and next performed the 25 immunoblot-based screening, where we sought to identify the mAbs that can specifically 26 J o u r n a l P r e -p r o o f react with SARS-CoV-2 NP but not with other human coronaviruses including SARS-1

CoV. Of the 12 clones, three clones (#7, #9, and #98) were found to be completely 2 specific to SARS-CoV-2 NP exhibiting no cross-reactivity with other related viruses 3 ( Figure 1C ), while the remaining clones showed cross-reactivity only to SARS-CoV 4 (Supplementary figure 1B) . Isotype analysis revealed that mAb #9 belonged to IgG1 5 kappa isotype while both #7 and #98 belonged to IgG2b kappa isotype ( Figure 1D) . 6

We next performed an ELISA-based epitope mapping to determine the antibody binding 8 sites using recombinant SARS-CoV-2 NP and its deletion mutants (Supplementary figure  9 2). We found that our newly developed mAbs recognized three distinct regions in NP: 10 mAb #7 bound to 210-231 aa, and mAb #98 bound to 382-397 aa ( Figure 1E ). Since 11 mAb #9 did not react with many deletion mutants of CTD domain (264-365 aa), we 12 inferred that this problem could be due to the conformational changes due to 13 inappropriate protein folding in deletion mutants. To overcome this trouble, we produced 14 substitution mutants in which each region of the CTD was recombined with a 15 homologous region of MERS-NP and examined the reactivity of the antibodies. With this 16 design, ELISA analysis showed that mAb #9 bound to 335-348 aa (Supplementary figure  17 2). 18 We next confirmed the antigenic discrimination ability of our newly developed mAbs. 19

Multiple alignment of NPs derived from various human coronaviruses were carried out to 20 examine the identity of epitope regions. Consistent with specificity analysis in Figure 1C , 21 all the binding sites were found to be specific to SARS-CoV-2 (Supplementary figure 3A) . 22

The numbers of distinct aa contributing to specific recognition of mAb to SARS-CoV-2 23 NP but not SARS-CoV NP were four for mAb #7 and one each for mAb #9 and #98. 24

There were more than 5 aa differences in the antibody epitopes of other human 25 coronaviruses (Supplementary figure 3A) . To identify the critical residue of specificity in 26 the epitope of each mAb, we created site-directed mutation with single amino acid 1 substitution and examined the reactivity by ELISA. The results showed that Ala217 for 2 #7, Asn345 for #9, and Gln390 for #98 were critical residues to discriminate SARS-CoV 3 and SARS-CoV-2 (Supplementary figure 3B) . 4

We next investigated whether the antigenic epitopes were located on the exterior 5 surface of the nucleocapsid. Since the structure of full length nucleocapsid protein has 6 not been elucidated, homology modeling was carried out using previously reported 7 partial structures of SARS-CoV-2 NP (PDB ID; 6M3M, 6YUN) 23,24 . Molecular modeling 8 of dimeric SARS-CoV-2 NP revealed that binding regions for all three mAbs were 9 located on the surface of the protein ( Figure 1E ). Furthermore, these regions were 10 spatially separated in the 3D-structure, indicating the possibility to simultaneously use a 11 pair of different mAbs to develop antigen sandwich detection assays. 12

To estimate the reactivity of the mAbs with different clinical strains of SARS-CoV-2, we 14 compared the amino-acid sequences of NP derived from clinical isolates registered in 15 the NCBI database. A total of 8,127 complete genomes were registered in the NCBI 16 database till date. Shannon entropy analysis revealed that the entire amino-acid 17 sequences of NP were highly conserved except for three high frequency substitutions; 18 S194L, R203K, and G204R which were same as previously described (Supplementary 19 figure 4A) 25 . We observed that the epitope of each of the mAbs was completely 20 conserved and devoid of any mutation in the current circulating mutants of SARS-CoV-2 21 including 501Y.V1, 501Y.V2, and 501Y.V3 (Supplementary figure 4B) . Furthermore, all 22 binding sites were highly conserved among the different strains of SARS-CoV-2 with 23 more than 99% identity (Supplementary figure 5A). We next performed site-directed 24 mutagenesis to introduce the binding site mutations into SARS-CoV-2 NP and examined 25 the effect on the reactivity of mAbs by ELISA analysis (Supplementary figure 5B) . 26 J o u r n a l P r e -p r o o f Despite the mutations, our mAbs were able to bind to the mutated NPs at a rate of 1 99.9% for #7, 99.86% for #9 and 99.84% for #98. 2

The equilibrium dissociation constant (K D ) between selected antibodies and full-length 4 NP of SARS-CoV-2 was determined by Bio-Layer interferometry. K D for the antibody-5 antigen binding in mAbs #7, 9, and 98 was calculated as ; 4.4 × 10 -10 , 3.7 × 10 -10 and 6 1.6 × 10 -10 respectively, all of which were lower than that of the commercially available 7 mAbs ( Figure 2A and Supplementary figure 6A) and the latter showed cross-reactivity 8 only to SARS-CoV NP (Supplementary figure 6B) . These findings reveal that our mAbs 9 had more specific and high affinity binding to SARS-CoV-2 NP than the commercial 10

We next performed immunoblot analysis with cell lysates from SARS-CoV-2 infected 12 cells. All the three mAbs detected a 46 kDa protein band consistent with the molecular 13 mass of SARS-CoV-2 NP ( Figure 2B ). We subsequently tested the applicability of these 14 mAbs in immunofluorescence analysis using SARS-CoV-2-infected Vero E6-TMPRSS2 15 cells and found that #7 and #98 exhibited prominent and specific staining of the NP 16 antigen in infected cells ( Figure 2C ). Additionally, mAb #98 was able to detect SARS-17

CoV-2 in infected cells in the paraffin-embedded lung tissue of a COVID-19 patient by 18 immunohistochemical analysis ( Figure 2D ). 19

Since we had observed the different spatial binding of our mAbs in epitope localization 21 analysis ( Figure 1E ), we exploited this feature to develop an antigen-capture sandwich 22 ELISA ( Figure 3A ). Therefore, we evaluated the optimal pair of mAbs that can be 23 employed for this purpose, by testing all possible combinations of immobilized and 24 labeled mAbs. The combination of #9/#98 exhibited best signal-to-noise (S/N) ratios as 25 compared to other pairs ( Figure 3B ). We used this combination to establish the SARS-26

CoV-2 NP antigen-capture ELISA with mAb #9 in the stationary phase and mAb #98 as 1 the conjugate with HRP. We next determined the antigen detection threshold for this 2 assay using serially diluted recombinant SARS-CoV-2 NP. The antigen-capture ELISA 3 detected a volume of NP as low as 3.2 pg/mL ( Figure 3C ). SARS-CoV-2 virions 4 inactivated by adding a detergent Nonidet P 40 (NP-40) were further examined by the 5 ELISA system and the detection limit of the assay was found to be 3.3 ×10 4 copies/mL 6 ( Figure 3C ). Furthermore, we validated the specificity of our ELISA by testing simulated 7 naso-pharyngeal swab specimens prepared by adding either the recombinant NP of 8 other human coronaviruses or virions of other human coronaviruses and common 9 respiratory viruses ( Figure 3D ). Additionally, the ELISA was able to detect all the three 10 major variants of concern (501Y.V1-3) ( Figure 3E ). 11

We next evaluated the clinical performance of the ELISA assay using specimens that Finally, we examined whether the antibody set could be applied to LFIA, which could 2 serve as a POCT device. We utilized silver halide photography technology for output 3 signal amplification in our LFIA 26,27 ( Figure 4A and Supplementary Figure 7A , B). In this 4 technology, silver ions are allowed to adhere to the surface of gold nanoparticles (approx. 5 0.05 µm in diameter) which allows the electrons from the solution to reduce the silver 6 atoms. This causes further attachment and reduction within a period of 30 seconds, 7 resulting in the congregation of reduced silver ions upon the gold nanoparticles to cause 8 size enhancement (approx. 5-10 µm in diameter) that provides a remarkable 9 improvement in visibility ( Figure 4B , C). By combining the above technology with specific 10 mAb combination selected by antigen-capture ELISA, our LFIA provides superior visual 11 detection of antigen-antibody complexes ( Figure 4D ). 12

The LFIA showed no cross-reactivity to related human coronaviruses or other 13 respiratory viruses using simulated naso-pharyngeal swab specimens, indicating its high 14 specificity ( Figure 4E ). The detection limit of this LFIA was found to be approximately 15 6.25 pg/mL of recombinant NP ( Figure 4F ). Subsequent study with inactivated SARS-16

CoV-2 particles revealed that the lowest detection limit of virus copy number 17 corresponded to 6.3×10 4 copies/mL ( Figure 4G ). This was tested in parallel experiments 18 with commercially available LFIA kits; Abbott Panbio COVID-19 Ag Rapid Test, Roche 19 SARS-CoV-2 Rapid Antibody Test, SD Biosensor Standard Q COVID-19 Ag, and 20

Fujirebio Espline SARS-CoV-2; to reveal that our LFIA detected the lowest amount of 21 SARS-CoV-2 compared to the above mentioned commercial kits ( Figure 4G ). 22

Furthermore, our LFIA could detect all the three major circulating mutants of SARS-CoV-23 2; 501Y.V1-3 ( Figure 4H ). 24

We next evaluated the performance of the developed LFIA using clinical specimens 25 (nasopharyngeal swab) that had been diagnosed by RT-PCR. Our LFIA did not show 26 J o u r n a l P r e -p r o o f false positives (n=63), revealing that the specificity was 100 % ( Figure 4I ). Comparison 1 experiments using nasopharyngeal swab specimens (n=90) revealed that other antigen 2 detection kits did not show false positives too. Nevertheless, none had a sensitivity as 3 high as the LFIA developed in this study ( Figure 4I ). Notably, our LFIA performed better 4 when compared to other antigen detection kits in samples with intermediate viral load Ct 5 values (Ct = 28-31) and low viral load Ct values (Ct > 31) ( Figure 4I ). These results 6

indicate that the LFIA designed with our newly developed mAbs could be useful for rapid 7 and efficient detection of SARS-CoV-2 antigen. 8 9

Nearing a year since the outbreak, the COVID-19 pandemic continues to spread 11 unchecked causing serious health concerns worldwide. Apart from finding specific 12 antiviral agents and vaccines, establishing a test for immediate detection of the infected 13 and screening mass populations to initiate appropriate quarantine measures is 14 necessary to control the spread of infection. The World Health Organization stresses that 15 diagnostic testing for COVID-19 is critical to track the virus, understand its epidemiology 16 to inform case management and suppress transmission 28 . As of now RT-PCR is the 17 primary test available for establishing the diagnosis of COVID-19. Although NAT is 18 sensitive and accurate, it requires specific equipment and trained personnel in 19 laboratories with centralized services and takes a few hours to obtain results. Owing to 20 their simplicity and ease of use, LFIA based antigen detection kits can serve as POCT 21 that can provide immediate results for prompt therapeutic or prophylactic actions. These 22 advantages warrant the need for a reliable antigen detection kit that can supplement or 23 supplant molecular diagnostics. To date, several antigen detection kits for SARS-CoV-2 24 are commercially available however, almost all of them face the problem of cross-25 reactivity to other human coronaviruses, not revealing epitopes or specificities of 1 antibodies and may not be able to respond to fore coming viral mutations 8, 29 . 2

In the current study, we have developed robust antigen detection systems using newly 3 synthesized high-affinity mAbs that specifically target SARS-CoV-2 devoid of cross-4 reactivity with other human coronaviruses including SARS-CoV. While designing an 5

antigen detection system, NP appears to be a good choice as the target antigen 6 because it is abundantly expressed in replicating virions and is highly immunogenic. Due 7 to the above mentioned reasons, NP is widely being used in serological diagnostic tests 8 14 . However, due to its high homology with other human coronaviruses, mAbs generated 9

with whole NP of SARS-CoV-2 may potentially cross-react with antigens of other human 10 coronaviruses causing false-positive reactions in non-COVID-19 cases [30] [31] [32] . To 11 overcome the problem of cross-reactivity, we produced ∆N-NP (aa 121-419) by deleting 12 of the conserved homologous aa sequences at the N-terminal domain and used this 13 antigen to generate mAbs specific for SARS-CoV-2. We successfully created three 14 specific mAbs that exclusively react with SARS-CoV-2 NP and not with any of the other 15 related human coronaviruses. 16

Preparation of high-quality antigen is the most critical pre-requisite for creating specific 17 mAbs. Synthetic peptides containing predicted viral immunogenic epitopes are widely 18 used to immunize animals for commercial generation of mAbs 33, 34 . However, synthetic 19 peptides are often linear and therefore are not ideally representative of the native 20 features of antigens with regard to their actual spatial structures. Indeed, a previous 21 study has demonstrated that the anti-SARS-CoV-2 NP mAbs created with the antigenic 22

peptides was found to cross-react with other coronaviruses 35 . Also the study showed 23 that the sensitivity of the antigen-detection ELISA designed with antigenic peptide 24 derived mAbs was not so high (~ 100 ng/ml) 35 . To overcome these problems, we 25 synthesized the SARS-CoV-2 ∆N-NP with the wheat germ cell-free system. This system 26 makes use of a eukaryotic translation machinery to synthesize properly folded and 1 biologically active proteins structurally identical to those expressed in mammalian cells 2 18, 19 . Although the antigen we used in this study was N-terminally deficient, it is highly 3 likely to have a multimeric structure because of the presence of an oligomer-forming 4

domain at the C-terminal dimerization domain 36,37 . Since the epitopes for our newly 5 developed mAbs were exposed on the surface of the dimerized NP proteins, our 6 antibodies were able to bind with native viral antigens. Yet another salient feature of 7 these mAbs was that they detected the three major variants of concern (501Y.V1, 8

501Y.V2 and 501Y.V3) since these rampantly circulating mutants do not possess any 9 mutations in the epitope binding sites of our mAbs. These characteristics highlight the 10 practical applicability of our mAbs for developing rapid antigen detection assays for 11

COVID-19. 12

The overall sensitivity of our antigen detection ELISA was 75.0%. However, we 13 observed that the sensitivity increased with lower Ct values and a similar trend was However, further viral culture analysis is required to confirm this. The LFIA developed in 20 our study differs from its conventional counterparts by possessing output signal 21 amplification using Silver halide photography technology 26 . Output signal amplification 22

techniques augment the performance of LFIAs by increasing their sensitivity 39, 40 . 23

Our antigen detection assays can be expected to perform as a clinical diagnostic tool. 24

By detecting cultured SARS-CoV-2 particles as low as 6.3 × 10 4 copies/mL, our LFIA 25 was more sensitive than other commercially available antigen detection kits. 26

Furthermore, our LFIA showed high sensitivity using clinical specimens, especially in 1 samples with intermediate (Ct = 28-31) and low viral load (Ct > 31). On the other hand, 2 there were slight discrepancies in the performance of each LFIA while detecting SARS-3

CoV-2 in culture supernatants and clinical specimens. For example, Fujirebio showed 4 higher sensitivity than SD Biosensor in culture supernatants, while the latter performed 5 better than the former in clinical specimens. This may be in part attributable to the 6 property of clinical specimens such as viscosity or presence of assay inhibitors. Further 7 large scale studies will be necessary to precisely identify the factors that may affect the 8 performance of the assay in clinical samples including saliva and sputum. 9

Like RT-PCR, antigen detection tests also face the problem of handling infectious 10 material which can pose hazard to the handling persons. However, this could be 11 overcome by inactivating the virus in the swab soon after collection by immersing into 12 extracting solutions which contain surfactants. Previous reports have demonstrated that 13 more than 0.1% of the non-ionic surfactant such as NP-40 or TritonX-100 completely 14

inactivates SARS-CoV-2 41 . We used extraction buffer containing non-ionic surfactant 15 (0.5% for ELISA and 0.1% for LFIA) which did not cause any hindrance to the 16 performance of the antigen detection tests. Inactivation of SARS-CoV-2 was actually 17 verified by the extraction buffer used in our study (data not shown). 18

Our study has a few limitations. We have found that Ala217 for #7, Asn345 for #9 and 20

Gln390 for #98 were the critical residues to discriminate SARS-CoV-2 from SARS-CoV. Further information and requests for resources and reagents should be directed to, and 1 will be fulfilled by the lead contact, Akihide Ryo (aryo@yokohama-cu.ac.jp). 2

Monoclonal antibodies established in this study are available from Yokohama City 4

University and Kanto Chemical Co., Inc., under MTA. Antigen detection kit developed in 5 this study is commercially available from FUJIFILM Corporation (FUJIFILM, cat# 6 16696722). 7

Original/source data for multiple sequence alignment and structural model of SARS-9

CoV-2 NP in the paper are available from DOI:10.17632/7b67yg29d6.1. 10

Clinical specimens of nasopharyngeal swabs from 252 individuals with suspected SARS-13

CoV-2 infection regardless of the onset of the disease, were retrieved for this study. Each viral culture were carried out in 5 % CO 2 at 37°C for SARS-CoV-2, RSV, IFAV, and 20 IFBV, at 33°C for OC43, 229E, HRV14, and HRV16. 21 were generated using the PrimeSTAR Mutagenesis Basal kit (Takara Bio, Otsu, Japan). 5

In vitro transcription and cell-free protein synthesis were performed as previously 7 described 21,42 . For cell-free protein synthesis, WEPRO7240H and WEPRO7240G wheat 8 germ extract (CellFree Sciences, Yokohama, Japan) was used in the bilayer translation 9 method as previously described 42 . Synthesized proteins were confirmed by SDS-PAGE 10 followed by CBB staining with Rapid CBB KANTO 3S (Kanto chemical, Tokyo, Japan) 11 and immunoblotting. 12

His-tagged N-terminal deleted mutant of NP (∆N-NP; 121-419) for immunization were 13 synthesized by a bilayer dialysis method using the wheat cell-free system according to 14 manufacturer instructions. The protein purification was carried out using Ni-Sepharose 15

Fast Flow beads (Cytiva, Waukesha, WI, USA) as previously described 21 . Full-length 16 NP were synthesized as FLAG-GST tagged proteins and purified by Glutathione 17

Immunization of BALB/c mice and generation of hybridomas producing anti-SARS-CoV-20 2-NP antibody were carried out as previously described 42-44 . For hybridoma screening, 21

indirect ELISA was performed using full-length NP and DHFR (negative control). These 22 proteins were diluted with PBS (1 µg/mL) and then immobilized to ELISA plate (Thermo 23 3.13, 1.56, and 0.781 nM was measured for 3 min, followed by a 5-min-long dissociation 22

phase. All measurements were corrected for baseline drift by subtracting a reference 23 well. Data were analyzed using a 1:1 binding model with global fitting algorithms in the 24

ForteBio data analysis software. 25

Flag-GST tagged deletion and substitution mutants of SARS-CoV-2 NP were produced 1 by the wheat germ cell-free system. Expressed proteins were diluted with PBS (1:400) 2 and then immobilized to ELISA plate (Thermo Fisher Scientific, Rockford, IL, USA). 3

Following blocking with PBS-T containing 3 % skim milk for 1h, serially diluted 4 monoclonal antibodies (3000, 600, 120, 24, 4.8, 0.96 ng/mL) were added and incubated 5 for 1h. After three washes with PBS-T, wells were incubated with 100 µL of diluted HRP- 

Homology of nucleocapsid proteins among human Coronaviruses was analyzed by 2 multiple sequence alignment using the MUSCLE software 50 . Total 12,441 SARS-CoV-2 3 whole genome sequences were downloaded from NCBI as of August 19, 2020. Partially 4 sequenced genomes, sequences with ambiguous sites, and 100 % identical sequences 5

were removed for further analysis. Consequently, 8,127 SARS-CoV-2 sequences were 6 aligned using the MAFFT version 7 and MEGAX 51,52 . Shannon entropy score was 7 calculated for each position in the protein alignment as previously described 53 . 8

Each mAb was diluted in PBS to a concentration of 2.5 µg/mL, and then added to an 10 ELISA plate (clear or black) (Thermo Fisher Scientific, Rockford, IL, USA). After blocking 11 with 2% skim milk, 100 µL of antigen protein (2 ng/mL) diluted with PBS-T or blank 12 Tokyo, Japan) to give the test and control line, respectively. The membrane was then 25 dried at 40 ºC for 30 min to immobilize antibodies. A reagent pad including monoclonal 26 antibodies conjugated with colloidal gold (British Biocell Intonational, Crumlin, UK) was 1 placed upstream of test lines as sample application point. A test strip and two sealed 2 pots containing a reducing reagent (containing 0.47 mol/l Fe(NH 4 ) 2 (SO 4 ) 2 ) and a silver-3 ion reagent (0.31 mol/l AgNO 3 ) were placed in a cartridge (Supplementary Figure 9) . with viral transport medium, and then viral RNA was isolated from 140 µL of diluted 17 specimens by using QIAamp Viral RNA Mini Kit (QIAGEN, Düsseldorf, Germany). One 18 step RT-PCR was performed using the CFX96 Touch Real-Time PCR Detection System 19 (Bio-rad, CA, USA) and NIID-N2 set primer. 20

Commercially available rapid antigen detection kit of SARS-CoV-2 (Abbott Panbio 22 COVID-19 Ag Rapid Test, Roche SARS-CoV-2 Rapid Antigen Test, SD Biosensor 23

Standard Q COVID-19 Ag, and Fujirebio Espline SARS-CoV-2) were used according to 24 the manufacturers' instructions. For evaluation of clinical samples, each of the 25 specimens were diluted three times with each extraction buffer and then subjected. Test 26 line interpretations were made by at least two independent observers within the 1 stipulated time. 2 Quantification and statistical analysis 3 All statistical analyses were performed by using GraphPad Prism 8 software. Graph 4 data are presented as mean ± SD. Statistical details of the analyses can be found in the 5 figure legends. 6 24. Zinzula, L., Basquin, J., Bohn, S., Beck, F., Klumpe, S., Pfeifer, G., Nagy, I., 1

Bracher, A., Hartl, F. U., and Baumeister, W. (2021) High-resolution structure and 2 biophysical characterization of the nucleocapsid phosphoprotein dimerization 3 domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. 4

Biochem. Biophys. Res. Commun. 538, 54-62. In this study Yamaoka et al. report their highly specific, epitope characterized monoclonal antibodies that exclusively detect SARS-CoV-2. These monoclonal antibodies when used in a lateral flow immunoassay coupled with silver amplification, enhance the performance of rapid antigen detection tests for COVID-19.

A pneumonia outbreak associated with a new 11 coronavirus of probable bat origin

COVID-19-a very visible pandemic

2021) WHO Coronavirus 15 Disease (COVID-19) Dashboard | WHO Coronavirus Disease

Low performance of rapid antigen detection test as 19 frontline testing for COVID-19 diagnosis

Large SARS-CoV-2 outbreak caused by 21 asymptomatic traveler

Detection of 24 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Evaluation of rapid 28 diagnosis of novel coronavirus disease (COVID-19) using loop-mediated 29 isothermal amplification

BinaxNOWTM COVID-19 Ag CARD: Instructions for Use. US Food and Drug 38 Administration website

4 care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-5 molecular-tests-detection-sars-cov-2 Genetic Variants of SARS-CoV-2 May Lead 6 to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 -7 Letter to Clinical Laboratory Staff and Health Care Providers | FDA

Novel rapid 10 immunochromatographic test based on an enzyme immunoassay for detecting 11 nucleocapsid antigen in SARS-associated coronavirus

The Nucleocapsid Protein of 14 SARS-CoV-2: a Target for Vaccine Development

Liquid-liquid phase separation by SARS-CoV-2 17 nucleocapsid protein and RNA

Production 20 of monoclonal antibodies against GPCR using cell-free synthesized GPCR antigen 21 and biotinylated liposome-based interaction assay

Development of oligomannose-coated liposome-based nasal vaccine against 24 human parainfluenza virus type 3. Front. Microbiol. 4

Cell-free expression systems for eukaryotic 26 protein production

The Cell-Free Protein Synthesis System from 28 Wheat Germ

Human 31 protein factory for converting the transcriptome into an in vitro-expressed 32 proteome

35 Development of monoclonal antibody and diagnostic test for Middle East 36 respiratory syndrome coronavirus using cell-free synthesized nucleocapsid 37 antigen

Syndrome Coronavirus 2 May Cause False-Positive Results in Serological Assays

Crystal structure of SARS-CoV-2 nucleocapsid 44 protein RNA binding domain reveals potential unique drug targeting sites

Effects of SARS-CoV-2 mutations on protein structures and intraviral 7 protein-protein interactions

Novel 10 lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic 11 accuracy study

Development of a highly 13 sensitive immunochromatographic detection kit for H5 influenza virus 14 hemagglutinin using silver amplification

Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human 17 cases. WHO -Interim guidance

Evaluation of a 20 rapid diagnostic assay for detection of sars-cov-2 antigen in nasopharyngeal 21 swabs

Evaluation of inapparent nosocomial severe acute respiratory 24 syndrome coronavirus infection in Vietnam by use of highly specific recombinant 25 truncated nucleocapsid protein-based enzyme-linked immunosorbent assay

Analysis of Serologic 29 Cross-Reactivity Between Common Human Coronaviruses and SARS

Testing for responses to the wrong SARS-CoV-2 antigen? The Lancet

Generation of monoclonal antibodies of desired specificity 37 using chimeric polyomavirus-derived virus-like particles

Development and Validation 41 of a Rapid Immunochromatographic Assay for Detection of Middle East 42 Respiratory Syndrome Coronavirus Antigen in Dromedary Camels

Generation of antibodies against COVID-19 virus for 46 development of diagnostic tools

Structural characterization of 1 the C-terminal domain of SARS-CoV-2 nucleocapsid protein

Architecture and self-4 assembly of the SARS-CoV-2 nucleocapsid protein

Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Fluorescent 11 immunochromatography for rapid and sensitive typing of seasonal influenza 12 viruses

Development and evaluation 15 of silver amplification immunochromatography kit for foot-and-mouth disease virus 16 antigen detection

Inactivation 19 analysis of SARS-CoV-2 by specimen transport media, nucleic acid extraction 20 reagents, detergents and fixatives

Wheat germ 23 cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of 24 human parainfluenza virus type 3 for generation and characterization of 25 monoclonal antibody

27 Identification of the nature of modification that causes the shift of DNA 28 topoisomerase IIβ to apparent higher molecular weight forms in the M phase

Analysis 31 of M phase-specific phosphorylation of DNA topoisomerase II

Nucleocapsid Protein RNA-binding Dimerization Domain Suggests a Mechanism 36 for Helical Packaging of Viral RNA

Protein structure modeling with MODELLER. 38

The I-40 TASSER suite: Protein structure and function prediction

SWISS-MODEL and the Swiss-PdbViewer: 42 An environment for comparative protein modeling

UCSF Chimera -A visualization system for 45 exploratory research and analysis

CoV-2 by TMPRSS2-expressing cells

Development of genetic diagnostic 16 methods for detection for novel coronavirus 2019(nCoV-2019) in Japan

Development of one-step, real-time, quantitative reverse transcriptase PCR 20 assays for absolute quantitation of human coronaviruses OC43 and 229E